Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain, Nitin; Keating, Michael; Thompson, Philip; Ferrajoli, Alessandra; Burger, Jan; Borthakur, Gautam; Takahashi, Koichi; Estrov, Zeev; Fowler, Nathan; Kadia, Tapan; Konopleva, Marina; Alvarado, Yesid; Yilmaz, Musa; DiNardo, Courtney; Bose, Prithviraj; Ohanian, Maro; Pemmaraju, Naveen; Jabbour, Elias; Sasaki, Koji; Kanagal-Shamanna, Rashmi; Patel, Keyur; Jorgensen, Jeffrey; Garg, Naveen; Wang, Xuemei; Sondermann, Katrina; Cruz, Nichole; Wei, Chongjuan; Ayala, Ana; Plunkett, William; Kantarjian, Hagop; Gandhi, Varsha; Wierda, William.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artigo em Inglês | MEDLINE | ID: mdl-31141631
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.